Protara Announces Closing of $75 Million Public Offering

Group 1 - Protara Therapeutics, Inc. has closed its underwritten public offering of 13,043,479 shares at a price of $5.75 per share, generating approximately $75 million in gross proceeds before deductions [1] - The company has granted underwriters a 30-day option to purchase an additional 1,956,521 shares at the public offering price [1] - Protara plans to use the net proceeds from the offering to fund the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes [1] Group 2 - J.P. Morgan, TD Cowen, and Piper Sandler served as joint book-running managers for the offering, with LifeSci Capital as the lead manager and H.C. Wainwright & Co. as a manager [2] - The shares were issued under an effective shelf registration statement on Form S-3, declared effective by the SEC on November 14, 2023 [3]